Literature DB >> 25877672

Acute Migraine Treatment in Adults.

Werner J Becker1,2.   

Abstract

There are many options for acute migraine attack treatment, but none is ideal for all patients. This study aims to review current medical office-based acute migraine therapy in adults and provides readers with an organized approach to this important facet of migraine treatment. A general literature review includes a review of several recent published guidelines. Acetaminophen, 4 nonsteroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, acetylsalicylic acid [ASA], naproxen sodium, and diclofenac potassium), and 7 triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan) have good evidence for efficacy and form the core of acute migraine treatment. NSAID-triptan combinations, dihydroergotamine, non-opioid combination analgesics (acetaminophen, ASA, and caffeine), and several anti-emetics (metoclopramide, domperidone, and prochlorperazine) are additional evidence-based options. Opioid containing combination analgesics may be helpful in specific patients, but should not be used routinely. Clinical features to be considered when choosing an acute migraine medication include usual headache intensity, usual rapidity of pain intensity increase, nausea, vomiting, degree of disability, patient response to previously used medications, history of headache recurrence with previous attacks, and the presence of contraindications to specific acute medications. Available acute medications can be organized into 4 treatment strategies, including a strategy for attacks of mild to moderate severity (strategy one: acetaminophen and/or NSAIDs), a triptan strategy for patients with severe attacks and for attacks not responding to strategy one, a refractory attack strategy, and a strategy for patients with contraindications to vasoconstricting drugs. Acute treatment of migraine attacks during pregnancy, lactation, and for patients with chronic migraine is also discussed. In chronic migraine, it is particularly important that medication overuse is eliminated or avoided. Migraine treatment is complex, and treatment must be individualized and tailored to the patient's clinical features. Clinicians should make full use of available medications and formulations in an organized approach.
© 2015 American Headache Society.

Entities:  

Keywords:  acute; adult; migraine; nonsteroidal anti-inflammatory drug; treatment; triptan

Mesh:

Substances:

Year:  2015        PMID: 25877672     DOI: 10.1111/head.12550

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  29 in total

Review 1.  Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response.

Authors:  Matilde Capi; Martina Curto; Luana Lionetto; Fernando de Andrés; Giovanna Gentile; Andrea Negro; Paolo Martelletti
Journal:  Ther Adv Neurol Disord       Date:  2016-06-03       Impact factor: 6.570

2.  Acute migraine medication adherence, migraine disability and patient satisfaction: A naturalistic daily diary study.

Authors:  Elizabeth K Seng; Matthew S Robbins; Robert A Nicholson
Journal:  Cephalalgia       Date:  2016-08-03       Impact factor: 6.292

Review 3.  Sumatriptan/Naproxen Sodium: A Review in Migraine.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2016-01       Impact factor: 9.546

4.  Improved Efficacy of Pregabalin by Restoring Plasma Vitamin D Levels in Migraine: a Case Report.

Authors:  Antonio Siniscalchi; Piergiorgio Lochner; Erika Cione; Adelia Michniewicz; Vincenzo Guidetti; Luca Gallelli
Journal:  Psychopharmacol Bull       Date:  2019-06-20

Review 5.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

6.  Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial.

Authors:  Ramesh Boinpally; John Spaventa; Kayla Chen; Matthew Butler
Journal:  Clin Drug Investig       Date:  2021-05-05       Impact factor: 2.859

7.  Intravenous lidocaine vs. NSAIDs for migraine attack in the ED: a prospective, randomized, double-blind study.

Authors:  Sultan Tuna Akgol Gur; Elif Oral Ahiskalioglu; Muhammed Enes Aydin; Abdullah Osman Kocak; Pelin Aydin; Ali Ahiskalioglu
Journal:  Eur J Clin Pharmacol       Date:  2021-09-16       Impact factor: 2.953

8.  Electroacupuncture Pretreatment at GB20 Exerts Antinociceptive Effects via Peripheral and Central Serotonin Mechanism in Conscious Migraine Rats.

Authors:  Lu Liu; Pei Pei; Luo-Peng Zhao; Zheng-Yang Qu; Yu-Pu Zhu; Lin-Peng Wang
Journal:  Evid Based Complement Alternat Med       Date:  2016-10-24       Impact factor: 2.629

9.  Efficacy of (S)-Lacosamide in preclinical models of cephalic pain.

Authors:  Aubin Moutal; Nathan Eyde; Edwin Telemi; Ki Duk Park; Jennifer Y Xie; David W Dodick; Frank Porreca; Rajesh Khanna
Journal:  Pain Rep       Date:  2016-06

Review 10.  Roads Less Traveled: Sexual Dimorphism and Mast Cell Contributions to Migraine Pathology.

Authors:  Andrea I Loewendorf; Anna Matynia; Hakob Saribekyan; Noah Gross; Marie Csete; Mike Harrington
Journal:  Front Immunol       Date:  2016-04-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.